Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487746 | 0.98 | — | — | |
| SCHEMBL927321 | 0.95 | KMT2A (0.48) | CA1CA2CA4KMT2ATLR4 | |
| SCHEMBL7911393 | 0.95 | KMT2A (0.48) | CA1CA2CA4KMT2ATLR4 | |
| SCHEMBL1325684 | 0.90 | — | — | |
| Sulfurous Acid SCHEMBL8579288 | 0.86 | CA1 (0.38) | CA1CA2CA4KMT2ATLR4 | |
| SCHEMBL17656247 | 0.84 | KMT2A (0.39) | CA1CA2CA4KMT2ATLR4 | |
| SCHEMBL17656195 | 0.84 | KMT2A (0.39) | CA1CA2CA4KMT2ATLR4 | |
| SCHEMBL3628061 | 0.79 | — | — | |
| Acetic Acid SCHEMBL15703783 | 0.79 | CREBBP (0.36) | CA1CA2CA4KMT2AMCL1 | |
| SCHEMBL19513384 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831167-B1 | LIQUID PHASE PROCESS FOR THE SYNTHESIS OF ANNULATED PYRIDINES OVER ZEOLITE TYPE MOLECULAR SIEVE CATALYSTS | COUNCIL SCIENT IND RES (IN) | 2011-07-13 | — | — | EP | disclosed |
| US-7491828-B2 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2009-02-17 | — | — | US | disclosed |
| US-20060149068-A1 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149068-A1 | Liquid phase process for the synthesis of annulated pyridines over molecular sieve catalysts | AURKA, CDK4, SKP2 | CA1 1966/4885CA2 2530/4885CA4 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.